Search

Financing supports advancement of lead programs LTX-002 and LTX-001 to first-in-human trials WORCESTER, Mass., Oct. 30, 2024 /PRNewswire/ -- Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients [...]

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders -- BOSTON, Oct. 30, 2024 /PRNewswire/ [...]

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 [...]

PALO ALTO, Calif. , Aug. 22, 2024 /PRNewswire/ -- Neuvivo, a biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment [...]

Financing led by Novo Holdings, including new investment from EQT Life Sciences -- LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK [...]

FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI https://bit.ly/BrainstormCell-Therapeutics-Initiation https://bit.ly/Regenerative-Medicine-Stem-Cells-and-ALS-Thematic LONDON, June 14, 2024 /PRNewswire/ -- INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal [...]

DARIEN, Conn., May 28, 2024 /PRNewswire/ -- Medical device maker CEFALY Technology announced a collaboration with Genesis Women's Shelter & Support in Dallas, Texas to help domestic violence survivors living [...]

DARIEN, Conn., May 21, 2024 /PRNewswire/ -- Medical device maker CEFALY Technology announced a new initiative, CEFALY Cares, which will assist and empower people living with migraine around the United [...]

SAN DIEGO, May 8, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4159262-1&h=2215513145&u=http%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.(Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational [...]

Patient dosing has been initiated with GM-1020, a novel oral NMDA receptor antagonist Initial results of the Phase 2a trial anticipated to be available in the 2[sup.nd] half of 2024 [...]

Ketamir-2 is a potential treatment for certain major mental health disorders impacting millions of people in the U.S. MIAMI, April 2, 2024 /PRNewswire/ --MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)('MIRA' or the [...]

BARCELONA, Spain and DÈ£SSELDORF, Germany, Feb. 29, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and [...]

Announces Research Collaboration with Pharmaseed to Conduct Pre-Clinical Studies on the Use of Ketamir for Patients with Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Studies will Investigate Antidepressant [...]

Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance PARIS, Feb. 1, 2024 /PRNewswire/ -- Vivet Therapeutics ('Vivet'), a clinical stage biotech company [...]

Funding to develop miniature implantable stimulator to unlock minimally invasive therapies for treatment-resistant neuropsychiatric disorders HOUSTON, Jan. 24, 2024 /PRNewswire/ -- Rice University today announced that https://c212.net/c/link/?t=0&l=en&o=4074851-1&h=1432948818&u=http%3A%2F%2Fmotifneuro.tech%2F&a=Motif+Neurotech, a neurotechnology company [...]

End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership [...]

TAMPA, Fla., Dec. 28, 2023 /PRNewswire/ -- Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, is pleased to announce [...]

Its Leading REN Wearable Device Brings Hope to Adolescents in the Fight Against a Leading Neurologic Disease NETANYA, Israel, Dec. 19, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4052425-1&h=356108011&u=https%3A%2F%2Ftheranica.com%2F&a=Theranica, a neuromodulation therapeutics company, announces [...]

Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a [...]

- Resource consumption will be reduced by 50% to accelerate ALS development - Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, Oct. 24, [...]

- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at [...]

FDA advisory committee (ADCOM) meeting to review NurOwn for ALS NEW YORK, Sept. 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell [...]

NEW YORK, Sept. 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the [...]

HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies [...]

CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ('Allos'), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded [...]

As the first nationwide virtual clinic specializing in neurodegenerative disease, Synapticure scales leadership team to meet the rapidly growing needs of patients, payers and providers CHICAGO, Sept. 6, 2023 /PRNewswire/ [...]

Due to favorable results of the interim analysis, the study will be completed as planned and submitted to the FDA and CE. TAMPA, Fla., July 18, 2023 /PRNewswire/ -- Neurolief, [...]

- There is currently no FDA approved treatment for ASIB in MDD. - Top-line data from this study is expected in the third quarter of 2023. NEW YORK, June 22, [...]

RADNOR, Pa., June 2, 2023 /PRNewswire/ --NRx Pharmaceuticals, Inc.(Nasdaq: NRXP) ('NRx Pharmaceuticals', the 'Company'), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call [...]

Enrollment completed nine months ahead of schedule with topline results anticipated Q4 2023 PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ('Harmony') (Nasdaq: HRMY), a pharmaceutical [...]

- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Accelerating Access to Critical Therapies for ALS (ACT [...]

Company Focuses on Innovative Diagnosis and Treatment of Neurodegenerative Diseases SCOTTSDALE, Ariz., March 30, 2023 /PRNewswire/ -- CND Life Sciences, a medical technology company pioneering the development of reliable skin-based [...]

Biologics License Application for NurOwn for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today [...]

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform - BDDS(TM) - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple [...]

- The randomized, double-blind, placebo-controlled study is evaluating SLS-005 in 160 patients over 24 weeks and Seelos anticipates delivering topline data in the second half of 2023. - Seelos will [...]

Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a company [...]

-Seelos is conducting a Phase I ethnobridging study in healthy Japanese and non-Asian subjects to evaluate the safety and pharmacokinetic profiles of SLS-002. NEW YORK, Feb. 6, 2023 /PRNewswire/ -- [...]

CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3766764-1&h=351743801&u=https%3A%2F%2Fwww.ionispharma.com%2F&a=Ionis+Pharmaceuticals%2C+Inc.(Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding [...]

Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date of June 23, 2023. HOUSTON, Jan. 24, 2023 [...]

Egret Therapeutics, a portfolio company of Turret Capital Management, Announces the Addition of Three New Members. NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on [...]

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3743743-1&h=2891705001&u=http%3A%2F%2Fwww.neurocrine.com%2F&a=Neurocrine+Biosciences%2C+Inc.(Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced [...]

NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, [...]

RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO's clinical-stage pipeline of neurodegenerative disease programs. Expanded Cohort 2 enrollment is complete; [...]

CAMBRIDGE, Mass., Nov. 16, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian [...]

LOS ANGELES and SAN FRANCISCO, Nov. 2, 2022 /PRNewswire/ -- The UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data [...]

-Seelos' SLS-002 (intranasal racemic ketamine) is believed to be the only drug in the psychedelic class currently being developed specifically to treat the symptoms of suicidality associated with major depression. [...]

- Acadia Healthcare is the Largest Stand-Alone Behavioral Health Company in the United States Operating a Network of Nearly 240 Behavioral Health Facilities in 39 States and Puerto Rico NEW [...]

https://www.financialnewsmedia.com/ News Commentary PALM BEACH, Fla., July 27, 2022 /PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to [...]

LONDON, July 19, 2022 /PRNewswire/ -- July 22 is devoted to Brain Health for All for World Brain Day (WBD). This year, in a free webinar, the World Federation of [...]

SLS-005 Study on the HEALEY ALS Platform is Expected to Complete Enrollment this Quarter; Top-Line Data Readout Expected Mid-2023 NEW YORK, July 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: [...]